Get started
Author

Michael Block

Institution: Bayer (Germany)
Observed institution: Bayer (Germany)
ORCID: 0009-0002-9902-7854
Observed ORCID: 0009-0002-9902-7854
OpenAlex ID: A5111460843
Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al. · Clinical Cancer Research · 2
Supplementary Figure S1 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Table S6 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Table S4 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Figure S2 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
Supplementary Table S5 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Table S2 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Table S3 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Table S7 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Table S1 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Works count: 10
Citation count: 2
H-index: 1
I10-index:
Year
Topic
Type